American Conference Institute’s 4th Annual Summit on Life Sciences IP Due Diligence

Melanie Rupert, Partner in Paul Hasting’s Intellectual Property Litigation Practice and Global Co-Chair of Talent Development, is proud to speak at ACI’s Life Sciences IP Due Diligence conference, taking place virtually on November 9-10, 2020. The conference aims to provide IP counsel with expert strategies for assessing, valuing and commercializing IP assets when conducting strategic IP due diligence, and features insights from IP and corporate counsel from companies including Akebia Therapeutics, Akorn Pharmaceuticals, Boehringer Ingelheim USA Corporation, Eli Lilly and Company, Genentech, Gilead Sciences, Merck, Novartis Pharmaceuticals, Roche, Sanofi, Takeda, and more. Melanie, alongside counsel from Eisai, will lead the highly anticipated new session “Evaluating COVID-19’s Impact on Biopharma Deal Making and Valuation of IP Assets.”